Stockscreener 앱 받기
10.62
2.61%
0.27
시간 외 거래:
10.61
-0.010
-0.09%
전일 마감가:
$10.35
열려 있는:
$10.38
하루 거래량:
237.91K
Relative Volume:
1.42
시가총액:
$323.34M
수익:
$6.67M
순이익/손실:
$-47.55M
주가수익비율:
-7.08
EPS:
-1.5
순현금흐름:
$-17.44M
1주 성능:
-8.13%
1개월 성능:
-9.54%
6개월 성능:
-17.80%
1년 성능:
+1,977%
1일 변동 폭
$10.16
$10.84
1주일 범위
$9.90
$12.39
52주 변동 폭
$8.72
$21.40
Crescent Biopharma Inc Stock (CBIO) Company Profile
명칭
Crescent Biopharma Inc
전화
617-430-5595
주소
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
10.62 | 315.12M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Piper Sandler | Overweight |
| 2026-01-21 | 개시 | Guggenheim | Buy |
| 2025-08-25 | 개시 | Jefferies | Buy |
| 2025-08-11 | 개시 | H.C. Wainwright | Buy |
| 2025-07-14 | 개시 | Wedbush | Outperform |
| 2025-06-25 | 개시 | Stifel | Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2024-07-26 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-22 | 개시 | CapitalOne | Overweight |
| 2021-11-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-05 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-12-18 | 개시 | H.C. Wainwright | Buy |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-07-26 | 개시 | SunTrust | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
| 2015-03-17 | 재확인 | Stifel | Buy |
모두보기
Crescent Biopharma Inc 주식(CBIO)의 최신 뉴스
Crescent Biopharma (NASDAQ: CBIO) registers 19.58M resale shares from private placement - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Upgraded to Hold at Wall Street Zen - MarketBeat
HC Wainwright Has Optimistic Outlook of CBIO Q1 Earnings - Defense World
Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewswire
HC Wainwright Issues Optimistic Estimate for CBIO Earnings - MarketBeat
GLYC SEC FilingsGlycomimetics 10-K, 10-Q, 8-K Forms - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Given New $22.00 Price Target at HC Wainwright - Defense World
Crescent Biopharma (NASDAQ: CBIO) registers 19.58M resale shares after $185M placement - Stock Titan
CBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Price Target Lowered to $22.00 at HC Wainwright - MarketBeat
H.C. Wainwright cuts Crescent Biopharma stock price target to $22 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Crescent Biopharma stock price target to $22 - Investing.com Australia
Crescent BiopharmaFinancial Details - Crunchbase
A Look At Sichuan Kelun-Biotech Biopharmaceutical’s Valuation After The Crescent Biopharma Oncology Partnership - simplywall.st
Guggenheim Remains a Buy on Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma (CBIO) Posts US$10.8m Q4 Revenue Against Heavy Losses Challenging Bullish Narratives - simplywall.st
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Stifel cuts Crescent Biopharma stock price target on equity financing - Investing.com South Africa
Stifel cuts Crescent Biopharma stock price target on equity financing By Investing.com - Investing.com Canada
Crescent Biopharma: Q4 Earnings Snapshot - theheraldreview.com
Crescent Biopharma Inc recently disclosed that certain revenues recognized in its 2025 financial report actually originate from a $20 million upfront payment made by Kelun-Biotech under a licensing agreement between the two parties for the core asset Cr-00 - Bitget
CBIO: Expanded oncology pipeline and strong cash position support multiple clinical milestones into 2028 - TradingView
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent ... - Bluefield Daily Telegraph
Crescent Biopharma (Nasdaq: CBIO) ramps R&D with $185M raise and 2025 loss - Stock Titan
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Crescent Biopharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Crescent Biopharma (NASDAQ:CBIO) Stock Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Crescent Biopharma: Fourth Quarter Financial Results Overview - Bitget
Crescent Biopharma to Present at March Investor Conferences - Bitget
Cancer-focused biotech Crescent Biopharma plans March investor talks in Boston and Miami - Stock Titan
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors - ADVFN
Crescent Biopharma announces grants of inducement awards - TipRanks
New hires at Crescent Biopharma get 10-year stock options - Stock Titan
Crescent Biopharma doses first patient in ASCEND cancer trial - Investing.com Nigeria
Should I Buy CBIO? CBIO 2026 AnalysisIntellectia AI™ - Intellectia AI
Crescent Biopharma announces first patient dosed in Ascend Phase 1/2 clinical trial of CR-001 - marketscreener.com
Crescent Biopharma Announces First Patient Dosed In Ascend Phase 1/2 Clinical Trial Of CR-001 - TradingView
Crescent Biopharma Doses First Patient in ASCEND Trial of Solid Tumor Treatment - marketscreener.com
Crescent Biopharma doses first patient in ASCEND cancer trial By Investing.com - Investing.com Canada
Experimental cancer antibody CR-001 enters global trial in advanced solid tumors - Stock Titan
Will Crescent Biopharma Inc. (GKO0) stock remain on Wall Street radarWeekly Loss Report & Safe Entry Momentum Stock Tips - mfd.ru
Is Crescent Biopharma Inc. (GKO0) stock in buy zone after pullback2025 Technical Patterns & Weekly High Return Forecasts - mfd.ru
CBIO: Global oncology pipeline advances with CR-001 and ADCs, backed by strong funding and partnerships - TradingView
FMR LLC's Strategic Acquisition of Crescent Biopharma Inc Shares - GuruFocus
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Crescent Biopharma (CBIO) Price Target Increased by 10.69% to 29.92 - Nasdaq
Crescent Biopharma Inc (CBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):